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Background and Purpose—Protection devices are increasingly used in carotid artery stenting. However, no randomized
trial has been conducted to evaluate the efficacy of such devices, and arguments have also been formulated against their
routine use. We set out to investigate the complication rates associated with carotid artery stenting performed without
protection devices. Applicability of covered stents in the carotid system was also evaluated.
Methods—Between January 2001 and July 2003, 245 consecutive patients (260 hemispheres) underwent carotid artery
stenting. No protection devices were applied. Covered stents were implanted in 31 (12.1%) cases. The incidence of
complications during the intervention and the subsequent 30-day follow-up period was recorded.
Results—The technical success rate was 98.8%. One postprocedural nonneurological death (0.4%) occurred. Neurological
complications (inclusive of transient ischemic attacks) were observed in 14 cases (5.4%). The rate of major
complications (death, major stroke, and myocardial infarction) was 1.6% among the symptomatic and 1.5% among the
asymptomatic cases. The rate of minor strokes was 3.2% in the symptomatic and 1.5% in the asymptomatic group. Of
the neurological complications, 64.3% occurred postprocedurally. No ipsilateral neurological complications were
detected in the subgroup treated with covered stents.
Conclusions—Carotid artery stenting without protection devices appears to be safe. Most of the neurological complications
could not have been prevented with protection devices, because they occurred after the intervention. The application of
covered stents may reduce the rate of embolization-related complications in the periprocedural period. (Stroke. 2004;
35:2862-2866.)
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Angioplasty with stent placement is increasingly usedinstead of endarterectomy for the treatment of carotid
artery stenosis.1 Although most of the randomized studies
comparing endovascular treatment with endarterectomy are
still in progress, there are encouraging results in favor of the
endovascular approach.2,3 Improvements in the expertise of
the physicians performing the procedures, and developments
in endovascular technology, have led to decreases in the rates
of complications associated with carotid stenting.1 The most
important acute complications of carotid stenting are related
to the distal embolization of particles generated during the
procedure.4,5 Although endovascular protection devices may
reduce the extent of intraprocedural cerebral embolization,6,7
their application may also result in additional complica-
tions.8,9 Recent studies8,10 have focused mainly on the low
rates of complications associated with procedures in which
protection devices are used, and less attention has been paid
to other means of reducing embolization. Some studies did
not report the timing of the complications relative to the
intervention1 or failed to indicate complication rates sepa-
rately for symptomatic and asymptomatic or for high-risk and
low-risk patients.7 We studied the 30-day outcome of carotid
artery stenting performed without the use of protection
devices. To our knowledge, this is the first evaluation of the
use of covered stents for carotid stenosis.
Subjects and Methods
Between January 2001 and July 2003, 245 consecutive patients were
included in a single-center carotid artery stenting study. Patients
were included if they had symptomatic or asymptomatic, 60% to
99% (according to the North American Symptomatic Carotid End-
arterectomy Trial [NASCET]11 measurement method) stenosis of a
carotid artery. Exclusion criteria were the occurrence of a stroke
within 6 weeks, a previous major stroke within the territory of the
stenotic artery with no useful recovery of function, the presence of
visible thrombus at the carotid lesion site, carotid artery dissection,
vessel narrowing caused by external compression by a tumor, a life
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expectancy of 2 years due to a known preexisting condition, and
the inability or unwillingness of the patient to provide informed
consent. Patient evaluation, intervention, and follow-up were carried
out by a team of radiologists, neurologists, and neurosurgeons in
accordance with a standardized protocol. The patients gave their
written informed consent to the procedures, which followed institu-
tional guidelines.
Patient Evaluation
The relevant medical history was taken and a thorough neurological
examination was performed on all patients. Patients demonstrating
repetitive transient ischemic attacks referable to an ipsilateral carotid
stenosis were treated at the earliest opportunity. Duplex ultrasonog-
raphy of the carotid arteries in all cases was used to reveal
hemodynamically significant stenosis. Stenoses were considered
significant if visible plaque and luminal narrowing were seen and the
peak systolic velocity in the internal carotid artery exceeded 175
cm/s. Magnetic resonance angiography of the carotid arteries was
performed in 21 patients (8.6%), and computed tomographic (CT)
angiography in 5 cases (2.0%) because of uncertainty as to the
presence of significant stenosis on ultrasonographic evaluation, due
to plaque calcification or vessel tortuosity. CT or MRI of the brain
was carried out in all cases. Criteria for patients at high risk included
age80 years old, contralateral carotid occlusion, postendarterecto-
my restenosis, cervical radiation treatment, severe cardiac dysfunc-
tion (New York Heart Association class III/IV chronic heart failure,
acute myocardial infarction within 4 weeks, unstable angina, or a
coronary procedure within 4 weeks), and pulmonary disease causing
considerable functional limitation. Patient and lesion characteristics
are shown in Table 1.
Stenting Protocol
Treatment with aspirin 100 mg plus clopidogrel 75 mg or ticlopidine
2250 mg daily was started at least 4 days before the procedure and
continued for a minimum of 4 weeks postprocedure. If this combined
antiplatelet treatment had not been given before stenting, 100 mg
aspirin and 300 mg clopidogrel were administered on the day of the
intervention. All stenting procedures were performed under local
anesthesia by the same neuroradiologist, with experience in 4000
diagnostic cerebral angiographies and 15 proctored carotid stenting
procedures before this study. Percutaneous access was gained
through the femoral artery. Brachiocephalic angiography with intra-
cranial views and assessment of the collateral cerebral circulation
always preceded the stenting. The extent of the carotid artery
stenosis was measured with the NASCET11 method, and the plaque
surface morphology was noted (Table 1). All lesions found nonin-
vasively to be hemodynamically significant proved to be60% with
the NASCET method. The final percentage stenosis was based on the
angiographic findings. Carotid artery stenting was achieved by a
standard technique12 with low-profile devices and gentle manipula-
tion. Heparin 5000 IU was given intraarterially 1 to 2 during the
intervention. No protection devices were used. The following
appropriately-sized self-expandable stents were implanted during the
257 successful procedures: 207 (80.5%) Carotid Wallstents (Boston
Scientific), 31 (12.1%) Symbiot covered stents (Boston Scientific),
18 (7.0%) Precise stents (Cordis), and 1 (0.4%) Smart stent (Cordis).
Predilatation was applied in 14 (5.4%) and postdilatation in 245
(95.3%) cases. Stent overdilatation was avoided. The residual steno-
sis in all successfully treated vessels was 30%. Covered stents
were used at the discretion of the interventionalist. The covered stent
(Symbiot) applied features a self-expanding nitinol stent encased in
a thin porous polytetrafluoroethylene membrane. No such stent was
applied in 2001, 7 were implanted in 2002, and 24 were used from
January to July 2003. The vital signs were recorded regularly, the
cardiac rhythm was monitored continuously, and neurological as-
sessment was frequent during the intervention. Intravenous atropine,
up to 2 mg, was administered as necessary for bradycardia. Control
angiograms were recorded on procedure completion to evaluate
recanalization and to exclude embolization into intracranial vessels.
Three patients whose stenting failed technically subsequently under-
went carotid endarterectomy.
Patient Follow-Up
Control neurological examination was performed routinely 24 hours
and 30 days after stenting. If a patient exhibited a neurological
deterioration, brain CT and control angiography (in the event of
intraprocedural complications) or carotid ultrasonography were con-
ducted without delay. Heart rate and blood pressure were checked
regularly in the postinterventional period. Carotid duplex ultrasonog-
raphy was carried out routinely 4 weeks postprocedure. The inci-
dence of complications during the intervention and the subsequent
30-day follow-up period was recorded. A transient ischemic attack
was defined as a focal retinal or hemispheric event from which the
patient made a complete recovery within 24 hours. Minor stroke was
identified as a new neurological deficit that either resolved com-
pletely within 30 days or increased the National Institutes of Health
Stroke Scale score by 3. Major stroke was defined as a new
neurological deficit that persisted after 30 days and increased the
National Institutes of Health Stroke Scale score by 4. Complica-
tions were considered “intraprocedural” if they occurred between the
attainment of femoral arterial access and successful vascular access
site hemostasis. Complications arising at any time up to 30 days after
this period were regarded as “postprocedural.” Eight patients (3.3%)
missed the 30-day evaluation visit but presented later. For the 6
patients (2.4%) who did not attend for control, follow-up information
was obtained from their general practitioners.
Statistical Analysis
Proportions were compared by using 2 or Fisher exact tests, as
appropriate. Two-sided P values are reported. P0.05 was consid-
ered significant.
TABLE 1. Characteristics of Patients and Carotid Lesions
Patients
Population 245 (100%)
Male 140 (57.1%)
Age
MeanSD, y 65.09.4
Range, y 33–89
70–79 y 80 (32.7%)
80–89 y* 9 (3.7%)
Severe cardiac dysfunction* 8 (3.3%)
Severe pulmonary dysfunction* 3 (1.2%)
Lesions
Count 260 (100%)
Symptomatic 124 (47.7%)
Pathomechanism of stenosis
Primary atherosclerotic 249 (95.8%)
Postendarterectomy restenosis* 11 (4.2%)
Fibromuscular disease 0 (0%)
Cervical radiotherapy* 0 (0%)
Degree of stenosis†
MeanSD, % 83.28.9
90% 111 (42.7%)
Contralateral carotid occlusion* 33 (12.7%)
Plaque morphology by angiography
Smooth 58 (22.3%)
Irregular/ulcerated 202 (77.7%)
*Criteria for high-risk cases.
†As measured with the NASCET method.
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Results
Of the 260 arteries in the 245 patients, 257 in 242 patients
were treated successfully (technical success rate: 98.8%). The
procedure failed because of extreme vessel tortuosity in 2
cases and because of the inability to guide the stent through
a calcified subtotal occlusion in 1 patient. Sixty procedures
(23.1%) were conducted on high-risk patients, 37 in symp-
tomatic (29.8%) cases, and 23 in asymptomatic (16.9%)
cases.
The complications observed during the procedure and the
30-day follow-up are shown in Tables 2 and 3. The 1
postprocedural nonneurological death (0.4%), in a high-risk
patient, occurred because of hemorrhagic shock resulting
from uncontrollable bleeding of a previously unknown ade-
nocarcinoma of the sigmoid colon. Neurological complica-
tions arose in 14 cases (5.4%; 95% CI, 2.6 to 8.1%).
Myocardial infarction was not detected. The rate of major
complications (death, major stroke, and myocardial infarc-
tion) was 1.6% among the symptomatic (low-risk, 1.1%;
high-risk, 2.7%; P0.51) and 1.5% among the asymptomatic
(low-risk, 0%; high-risk, 8.7%; P0.03) cases (P1.0). The
rate of minor strokes was 3.2% in the symptomatic (low-risk,
3.4%; high-risk, 2.7%; P1.0) and 1.5% in the asymptomatic
(low-risk, 1.8%; high-risk, 0%; P1.0) group (P0.43). The
rate of major complications was 0.5% in the low-risk and
5.0% in the high-risk group (P0.04). The rate of minor
strokes was 2.5% and 1.7% in the low- and high-risk
populations, respectively (P1.0).
Of the 14 neurological complications, 5 (35.7%) occurred
intraprocedurally and the remainder after completion of the
intervention. Thirteen (92.9%) neurological complications
developed ipsilaterally to the stented carotid artery, 8 in cases
with 90% stenosis (7.2%) and 5 in those with 90%
stenosis (3.4%, P0.16). The rate of ipsilateral neurological
complications among the patients with irregular or ulcerated
plaques was 4.5% (9 of 202), whereas among those with
smooth lesions it was 6.9% (4 of 58; P0.50). All strokes
were ischemic. One major stroke occurred in a patient (No.
12, Table 3) who took only aspirin after discharge. Stent
occlusion was diagnosed in 2 patients within the 30-day
follow-up; one of them (No. 3, Table 3) experienced a major
stroke during coronary artery bypass surgery performed
under anticoagulant but not combined antiplatelet treatment;
the other remained symptom-free. Restenosis was not ob-
served. One patient experienced severe hypotension requiring
intensive care. Blood transfusion was necessary in 1 case
because of a considerable blood loss from the femoral
puncture site.
Of the 31 covered stents, 14 (45.2%) were implanted in
symptomatic cases; 23 (74.2%) were used for irregular/
TABLE 2. Complications Within 30 Days
Category
Symptomatic
(n124)
Asymptom-
atic (n136)
Overall
(n260)
no. % no. % no. %
Death 0 0.0 1 0.7 1 0.4
Neurological complications
Major strokes 2 1.6 1 0.7 3 1.2
Minor strokes 4 3.2 2 1.5 6 2.3
All ipsilateral strokes 5 4.0 3 2.2 8 3.1
TIAs 4 3.2 1 0.7 5 1.9
Other complications
Myocardial infarction 0 0.0
Angina 1 0.4
Severe hypotension 1 0.4
Procedure-related bleeding 1 0.4
Stent occlusion 2 0.8
Restenosis 0 0.0
Femoral AV fistula 1 0.4
TIAs indicates transient ischemic attacks.
TABLE 3. Neurological Complications Within 30 Days
No. Age, y Sex Risk Stenosis Type Plaque Category Side* Timing
1 55 M H Sympt Irregular Minor stroke Ipsilateral Postprocedural
2 57 F H Sympt Smooth TIA Ipsilateral Intraprocedural
3 63 F H Asympt Ulcerated Major stroke Ipsilateral Postprocedural
4 65 M L Sympt Irregular TIA Ipsilateral Postprocedural
5 66 F L Sympt Irregular TIA Ipsilateral Intraprocedural
6 68 F L Asympt Smooth TIA Ipsilateral Intraprocedural
7 69 M L Sympt Irregular Minor stroke Ipsilateral Postprocedural
8 71 F L Sympt Irregular Minor stroke Ipsilateral Postprocedural
9 72 M L Sympt Irregular Minor stroke Contralateral Postprocedural
10 72 M L Sympt Smooth TIA Ipsilateral Postprocedural
11 74 M L Asympt Smooth Minor stroke Ipsilateral Intraprocedural
12 78 F L Sympt Irregular Major stroke Ipsilateral Postprocedural
13 79 M L Asympt Irregular Minor stroke Ipsilateral Postprocedural
14 82 M H Sympt Irregular Major stroke Ipsilateral Intraprocedural
M indicates male; F, female; H, high-risk; L, low-risk; asympt, asymptomatic stenosis; sympt, symptomatic stenosis; TIA, transient
ischemic attack.
*Indicates whether the complication developed ipsi- or contralaterally to the stented carotid artery.
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ulcerated stenoses, and 8 (25.8%) were used in high-risk
cases. No ipsilateral neurological complications developed in
the patients receiving covered stents, as opposed to the 5.8%
complication rate (13 ipsilateral neurological symptoms with
226 treated vessels) with regular stents (P0.38). No tech-
nical difficulties were experienced with the use of covered
stents.
The rate of neurological complications was 2.0% (1 during
49 procedures) in 2001, 5.9% (6 of 102) in 2002, and 6.4% (7
of 109) from January to July 2003.
Discussion
The rate of all strokes and death, 4.8% among the symptom-
atic and 2.9% among the asymptomatic cases in our study,
involving low- and high-risk patients compares favorably
with the results obtained in the low-risk populations under-
going endarterectomy in the NASCET11 and Asymptomatic
Carotid Atherosclerosis Study (ACAS)13 investigations in
which the rate of all strokes and death was 5.8% for
symptomatic and 2.3% for asymptomatic patients,
respectively.
The release of microemboli composed of thrombotic and
plaque substances into the cerebral circulation is considered
to be the main cause of the early complications associated
with stenting and also with endarterectomy. The phases with
increased microembolic signals at stenting as detected by
transcranial Doppler include predilatation, stent deployment,
and postdilatation.6 In an attempt to reduce periprocedural
complication rates during stenting, cerebral protection de-
vices were developed, those most commonly used being
distal filters and occlusive distal balloons. A recent study10 of
815 stenting procedures with cerebral protection devices
revealed a 30-day stroke and death rate of 3.8% for symp-
tomatic and 3.2% for asymptomatic lesions. A review1 of the
global carotid artery stent registry by Wholey et al demon-
strated a 2.23% rate of strokes and procedure-related deaths
in 4221 cases undergoing protected carotid stenting, whereas
the corresponding rate among the 6753 cases treated without
protection was 5.29%. A systematic review7 of the early
outcome of carotid angioplasty and stenting in both symp-
tomatic and asymptomatic patients found that the combined
stroke and death rate with cerebral protection was 1.8%, that
is, significantly lower than the 5.5% in those treated without
protection devices. However, in addition to causing increases
in the intervention time, the technical complexity and the
cost, the application of protection devices may also lead to
complications, including hemodynamic intolerance due to
balloon occlusion or congested nets, spasm or dissection of
the carotid artery, and difficulties with retrieval of the
device.5,8,9 Furthermore, predilatation, which is often neces-
sary in protected stenting, and the removal of the protection
devices may result in embolization.9 Not all particles may be
removed from behind the balloon occlusion–type device, and
small particles (even though probably clinically insignificant)
may pass through the filter systems. Protection devices do not
prevent the late embolization of particles trapped in the stent
meshes. The Stenting and Angioplasty With Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
study3 found a 4.4% overall perioperative stroke and death
rate of stenting with protection devices in high-risk cases,
whereas in the asymptomatic subgroup the rate was as high as
5.8%.14
Our results indicate that postprocedural embolization may
be responsible for a significant proportion of the complica-
tions. Neurological complications could not have been pre-
vented with a protection system in 9 (64.3%) cases in our
series, because these were not intraprocedural complications.
Similarly, in a study15 of 111 patients stented without
protection devices, 10 (71.4%) of the 14 neurological com-
plications occurred postprocedure. The low intraprocedural
complication rate in our study may be related to several
factors. Low-profile devices were used, and predilatation of
the lesions was avoided whenever possible. The stents were
not overexpanded during postdilatation. As far as we are
aware, this is the first published report on the application of
(among others) covered Symbiot stents for carotid stenosis.
Covered stents prevent the passage of atherosclerotic material
through the stent mesh. In order not to obstruct the flow into
the external carotid artery and also because of their maximum
diameter of 6 mm, these stents were used for lesions involv-
ing only the internal carotid artery and not extending into the
common carotid artery. As a learning curve effect was not
seen in our series, the low complication rate observed with
covered stents is unlikely to be because of their more frequent
application toward the end of the study period. Our results
indicate that covered stents may safely and efficiently reduce
neurological complications due to embolizations during stent
deployment and postdilatation and also postprocedurally.
Their utilization may additionally decrease the restenosis rate.
Further studies are expected to provide more data on the use
of covered stents for carotid stenosis, although large case
numbers would be necessary to demonstrate statistically
significant differences in complication rates.
Concerning postprocedural complications, adherence to the
combined antiplatelet regimen appears important. In 2 cases
of postprocedual major strokes among our patients, the
combined antiplatelet medication had been interrupted. A
previous stenting study,16 in which solely aspirin was admin-
istered, reported high complication rates. The combination of
aspirin with clopidogrel, as compared with aspirin alone,
appears to reduce the thromboembolic potential (as measured
by transcranial Doppler) after carotid endarterectomy.17 This
may apply to carotid stenting, too. The results of our study
can be generalized to patients with atherosclerotic stenosis of
the carotid artery. To provide the best possible treatment for
the patients, collaboration within a multidisciplinary consul-
tation team is necessary during the patient evaluation, inter-
vention, and follow-up.
There are some limitations to our study. Transcranial
Doppler studies or brain MRI examinations with diffusion-
weighted sequences were not performed to detect cerebral
embolization. It has been documented4 that a majority of the
new lesions seen on postintervention MRI images are not
detected at neurological examination. Patients with a history
of stroke were treated at least 6 weeks after the event, which
may have resulted in a lower rate of complications as
compared with an earlier intervention. Although patients who
had failed to attend the 30-day check-up were reported to be
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symptom-free, the occurrence of minor neurological compli-
cations cannot be fully excluded.
No randomized study has as yet been conducted to inves-
tigate the efficacy of protection devices. Our study indicates
that carotid artery stenting without protection devices can be
performed within the complication rate limits (perioperative
stroke and death 6% for symptomatic and 3% for asymp-
tomatic patients) recommended by the American Heart As-
sociation for carotid endarterectomy18 and that complication
rates can be achieved that are similar to those observed with
protection devices. We propose that the application of cov-
ered stents may reduce embolization. Subgroup analysis of
the endarterectomy versus carotid stenting trials currently
under way is expected to provide data on the value of
protection devices. Developments in endovascular technol-
ogy, pharmacological management and expertise should lead
to further reductions in the complication rates associated with
carotid artery stenting.
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